Drug Trial Radar · NCT07317544
Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic Alopecia
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
227
Planned (sponsor's estimate)
Start
Dec 3, 2025
Primary completion
Jul 2028
Study completion Jul 2028
Sponsor
- Lead sponsor
- Absci Pty Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a first-in-human study of ABS-201, a new investigational medicine, in healthy adult men and women. Its main purpose is to find out whether ABS-201 is safe and well tolerated, as well as to understand how the body processes it and how it affects related biological markers. ABS-201 is being developed as a possible treatment for androgenetic alopecia (male- and female-pattern hair loss); its effect on hair growth has not yet been established. The study has two parts: in the single ascending dose (SAD) part, healthy adults receive one intravenous dose of ABS-201 or placebo; and in the multiple ascending dose (MAD) part, participants (including men with androgenetic alopecia) receive several subcutaneous doses of ABS-201 or placebo. The MAD part also evaluates the effect of ABS-201 on hair growth. The main questions it aims to answer are: What medical problems, if any, do participants experience when taking a single dose or many doses of ABS-201? How does the medication, ABS-201, compare to placebo (a look alike substance that does not contain any medication). Participants who qualify for the trial will receive either ABS-201 or a placebo, and visit the study clinic for scheduled checkups and tests for approximately 12 months in the single ascending dose (SAD) part and approximately 18 months in the multiple ascending dose (MAD) part. In the MAD part, participants receive repeated subcutaneous doses.
Conditions
- Androgenetic Alopecia (AGA)
- Healthy Volunteers - Male and Female
Interventions
SAD IV Dose 1 - 150mg ABS201 IV Single DoseDrug
ABS-201 is an IgG1 monoclonal antibody developed to specifically target the prolactin receptor (PRLR)
Placebo IVDrug
Matching placebo
ABS-201 SC Multiple DosesDrug
Multiple doses of ABS-201 for Subcutaneous injection
Placebo SC InjectionDrug
Subcutaneous Placebo injection for MAD arms
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence rate of treatment-emergent adverse events (TEAEs) and serious TEAEsTime frame: From enrollment to the end of the Study (SAD approximately 12 months, MAD approximately 18 months)
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Momentum Darlinghurst
Sydney, New South Wales, Australia · Recruiting
Nucleus Network Brisbane
Brisbane, Queensland, Australia · Recruiting
Sinclair Dermatology
Melbourne, Victoria, Australia · Recruiting
Nucleus Network
Melbourne, Victoria, Australia · Recruiting
DermCo Pty Ltd
South Perth, Western Australia, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.